Heart failure is a common and disabling condition with a dismal prognosis. Inhibition of the
renin-angiotensin-aldosterone system (RAAS) with angiotensin converting enzyme (ACE) …

Chronic heart failure is one of the most seri-ous cardiac problems encountered in clinical
practice. Modulation of the renin angiotensin system is a key element in the treatment of this …

Chronic heart failure (CHF) is a major cause of morbidity and mortality in western society. It
is now widely accepted that the renin-angiotensin-aldosterone system (RAAS) and, in …

The renin–angiotensin–aldosterone system (RAAS) is central to the pathogenesis of heart
failure (HF) and medications inhibiting RAAS are critical. Angiotensin-converting enzyme …

Angiotensin-converting enzyme inhibitors (ACE-inhibitors) are first-line treatment for chronic
heart failure (CHF) with a low left ventricular ejection fraction because they improve …

Although interruption of the renin-angiotensin system with angiotensin converting enzyme
(ACE) inhibitors has evolved as the therapy of choice in heart failure based on large-scale …

Heart failure treatment centers on antagonism of the renin‐angiotensin‐aldosterone system
and adrenergic nervous system. Angiotensin‐converting enzyme (ACE) inhibitors have …

For over a decade angiotensin converting enzyme (ACE) inhibitors have revolutionised the
treatment of chronic heart failure, becoming a frontline therapy on the basis of several key …

Heart failure remains a significant cause of morbidity and mortality, despite major advances
in therapy. Angiotensin II, the principal mediator of the renin‐angiotensin system, exerts both …

Chronic heart failure (CHF) has become one of the largest medical and epidemiological
problems of the Western world, carrying a high morbidity and mortality. Traditional treatment …